Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.

Détails

ID Serval
serval:BIB_2B7C3E6161FB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.
Périodique
Journal of Clinical Oncology
Auteur(s)
Martinelli G., Schmitz S.F., Utiger U., Cerny T., Hess U., Bassi S., Okkinga E., Stupp R., Stahel R., Heizmann M., Vorobiof D., Lohri A., Dietrich P.Y., Zucca E., Ghielmini M.
ISSN
1527-7755[electronic], 0732-183X[linking]
Statut éditorial
Publié
Date de publication
2010
Volume
28
Numéro
29
Pages
4480-4484
Langue
anglais
Résumé
PURPOSE: We report the long-term results of a randomized clinical trial comparing induction therapy with once per week for 4 weeks single-agent rituximab alone versus induction followed by 4 cycles of maintenance therapy every 2 months in patients with follicular lymphoma.
PATIENTS AND METHODS: Patients (prior chemotherapy 138; chemotherapy-naive 64) received single-agent rituximab and if nonprogressive, were randomly assigned to no further treatment (observation) or four additional doses of rituximab given at 2-month intervals (prolonged exposure).
RESULTS: At a median follow-up of 9.5 years and with all living patients having been observed for at least 5 years, the median event-free survival (EFS) was 13 months for the observation and 24 months for the prolonged exposure arm (P < .001). In the observation arm, patients without events at 8 years were 5%, while in the prolonged exposure arm they were 27%. Of previously untreated patients receiving prolonged treatment after responding to rituximab induction, at 8 years 45% were still without event. The only favorable prognostic factor for EFS in a multivariate Cox regression was the prolonged rituximab schedule (hazard ratio, 0.59; 95% CI, 0.39 to 0.88; P = .009), whereas being chemotherapy naive, presenting with stage lower than IV, and showing a VV phenotype at position 158 of the Fc-gamma RIIIA receptor were not of independent prognostic value. No long-term toxicity potentially due to rituximab was observed.
CONCLUSION: An important proportion of patients experienced long-term remission after prolonged exposure to rituximab, particularly if they had no prior treatment and responded to rituximab induction.
Mots-clé
non-hodgkins-lymphoma, stem-cell transplantation, randomized phase-ii, event-free survival, maintenance therapy, indolent lymphoma, chemotherapy, fludarabine, interferon, cancer
Pubmed
Web of science
Création de la notice
27/10/2010 15:20
Dernière modification de la notice
03/03/2018 15:25
Données d'usage